Phase 2 Vasculitis Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- Adults between 18 and 75 years old who have been diagnosed with a condition called GPA (Granulomatosis with Polyangiitis) or MPA (Microscopic Polyangiitis), based on recognised 2022 medical classification guidelines
- People who have tested positive for specific proteins in their blood called ANCA antibodies
- People with GPA or MPA whose disease is currently severe and active
Who may not be able to join:
- People who have a condition that would make it impossible to safely clear certain medications from their body before the treatment, or that would otherwise make them unsuitable for this type of therapy (confirm with trial site)
- People who have had allergic reactions to, or medical reasons to avoid, any of the medications or treatments used in this trial
- People who have other autoimmune diseases (where the immune system attacks the body) that currently require treatment
- People who have other health conditions — unrelated to GPA or MPA — that could make it unsafe for them to receive this type of treatment
- People whose kidneys, liver, or other organs are not working well enough to safely take part in the trial (confirm with trial site)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Novartis Pharmaceuticals, Novartis Pharmaceuticals
Phone: 1-888-669-6682
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Event-free survival (EFS)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.